Dr. Raje Discusses Anti-CD38 Antibodies in Myeloma

Noopur Raje, MD
Published: Monday, Dec 08, 2014



Noopur Raje, MD, director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.

As single-agents, the anti-CD38 antibodies have elicited responses in approximately 40% of patients. Furthermore, at the ASH meeting, Raje notes that the CD38 antibodies in combination with lenalidomide and dexamethasone have shown responses in nearly 80% of patients.

The leading anti-CD38 agents being explored for myeloma include daratumumab and SAR650984. Both agents have shown promising efficacy as monotherapies and in combinations. This level of efficacy has never been seen before in multiple myeloma, notes Raje.

<<< View more from the 2014 ASH Annual Meeting



Noopur Raje, MD, director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.

As single-agents, the anti-CD38 antibodies have elicited responses in approximately 40% of patients. Furthermore, at the ASH meeting, Raje notes that the CD38 antibodies in combination with lenalidomide and dexamethasone have shown responses in nearly 80% of patients.

The leading anti-CD38 agents being explored for myeloma include daratumumab and SAR650984. Both agents have shown promising efficacy as monotherapies and in combinations. This level of efficacy has never been seen before in multiple myeloma, notes Raje.

<<< View more from the 2014 ASH Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x